First bispecific antibody approved in EU to combat leading causes of vision loss
Roche’s Vabysmo® (faricimab) has been approved in Europe as a four-monthly treatment for wet age-related macular degeneration and diabetic macular oedema.
List view / Grid view
Roche’s Vabysmo® (faricimab) has been approved in Europe as a four-monthly treatment for wet age-related macular degeneration and diabetic macular oedema.
Similar rates of skin improvement at week 100 indicate Skyrizi® (risankizumab) has consistent long-term efficacy in psoriatic arthritis patients.
Dual checkpoint inhibitor blockade could be a promising first-line and salvage therapeutic option for advanced Merkel cell carcinoma, say researchers.
The critical need to rapidly develop new biological therapeutics was emphasised during the COVID-19 pandemic, prompting a sea-change in the speed with which development of complex biological medicines occurs. In parallel, the increasing demand for new molecular formats, such as multi-specific antibodies, to tackle a wide range of disease modalities…
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…
Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.
The acquisition will boost Gilead’s capabilities in exploring checkpoint agonist antibodies for treating patients with autoimmune disease, complementing its inflammation research and development strategy.
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
Phase I human challenge study shows a single subcutaneous injection of the monoclonal antibody L9LS provides at least short-term protection against malaria.
Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.
Phase II results suggest litifilimab safely and effectively reduces skin disease activity in cutaneous lupus erythematosus (CLE) patients.
Results from several haemophilia trials have been presented at the International Society on Thrombosis and Haemostasis (ISTH) Annual Congress 2022, here EPR summarises some of the key developments.
Phase III trial data shows Dupixent® (dupilumab) has the potential to improve signs of eosinophilic oesophagitis (EoE) and support healthy weight gain in children with the condition.
Takeda has announced late-breaking Phase III trial data showing that Takhzyro® (lanadelumab) reduces hereditary angioedema (HAE) attacks by roughly 95 percent in children aged two to
Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.